Transparency Under Scrutiny: The Biontech/Pfizer Contract

The European Union’s commitment to transparency is facing renewed scrutiny following a recent court ruling regarding access to documents related to a major vaccine procurement deal.The case revolves around a contract between the EU Commission and Biontech/Pfizer, finalized in the spring of 2021, for the supply of up to 1.8 billion doses of the COVID-19 vaccine. The agreement, valued at an estimated €35 billion, has been a subject of public interest and debate.

The Core of the Dispute: Text Messages and Access to Information

At the heart of the legal challenge is a request for access to text messages reportedly exchanged between EU Commission President Ursula von der Leyen and Pfizer CEO Albert Bourla. These communications, as reported by the New York Times, were allegedly instrumental in securing the vaccine agreement.A journalist, representing the New York Times, formally requested access to these messages, spanning the period from January 1, 2021, to May 11, 2022.

The EU Commission initially denied the request, asserting that it did not possess the requested documents. This denial triggered a legal challenge, with the journalist and the new York Times taking the case to the Court of the European Union.

Court Ruling: A Blow to the Commission’s Position

The Court of the European Union has now ruled against the Commission, stating that the clarification provided for not releasing the requested text messages was not sufficiently convincing. The court has declared the Commission’s decision to withhold the documents unlawful. However, it’s crucial to note that this judgment is not yet final, leaving room for potential appeals and further legal proceedings.

The Commission did not give a plausible explanation of why it did not have the requested documents… the court declared the decision not to publish the requested messages.

Implications for Transparency and Accountability

This ruling raises significant questions about transparency and accountability within the EU Commission, notably concerning high-value contracts and communications between top officials and corporate executives. The demand for transparency in vaccine procurement is not unique to the EU. Similar debates have unfolded globally, with citizens and watchdogs demanding greater insight into the negotiation and awarding of contracts related to public health.

According to a recent report by Transparency International, public trust in government institutions is closely linked to the perceived level of openness and accountability. Cases like this one can erode public confidence if not handled with utmost transparency.

Looking Ahead: Potential Repercussions and Future Actions

The EU commission now faces the challenge of responding to the court’s ruling and possibly releasing the requested text messages. The outcome of this case could set a precedent for future access-to-information requests and influence the way the Commission handles sensitive communications related to major agreements. The public, along with transparency advocates, will be closely watching the next steps in this unfolding saga.